This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jounaidi, Y. Articles by Waxman, D. J. Search for Related Content PubMed PubMed Citation Articles by Jounaidi, Y. Articles by Waxman, D. J.

Retroviral Transfer of Human Cytochrome P450 Genes for Oxazaphosphorine-based Cancer Gene Therapy¹

Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts 02215

Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer prodrugs that are bioactivated in the liver by specific cytochrome P450 enzymes (CYPs). The therapeutic activity of these antitumor agents can be compromised by a low therapeutic index that is, in part, due to the systemic distribution of activated drug metabolites. Here, recombinant retroviruses were used to deliver six different CPA- or IFA-metabolizing human CYP genes to 9L gliosarcoma cells: 2B6, 2C8, 2C9, 2C18 (Met³⁸⁵ and Thr³⁸⁵ alleles), 2C19, and 3A4. Intratumoral cytochrome P450 expression conferred substantial sensitivity to CPA cytotoxicity, with the most dramatic effects seen with CYP2B6. Strong CPA chemosensitivity was also seen following transduction of CYP2C18-Met, despite a very low level of CYP protein expression (>60-fold lower than that of 2B6). In contrast to CPA, the cytotoxicity of IFA was greatest toward tumor cells transduced with CYP3A4, followed by CYPs 2B6 and 2C18-Met. A substantial further increase in chemosensitivity was achieved upon transduction of 2B6 or 2C18-Met-expressing tumor cells with P450 reductase, which provided for more efficient intratumoral prodrug activation and cytotoxicity at lower drug concentrations. With 2B6- plus P450 reductase-transduced tumor cells, CPA but not IFA conferred a strong cell contact-independent bystander cytotoxic effect on non-P450-expressing 9L cells. CPA treatment of tumors that were transduced with 2B6 or 2C18-Met together with P450 reductase and were grown s.c. in immunodeficient mice resulted in a large enhancement of the liver P450-dependent antitumor effect seen with control 9L tumors, with no apparent increase in host toxicity (growth delay of >25–50 days in P450-expressing tumors versus 5–6 days without P450). CYP2B6 plus P450 reductase and CYP2C18-Met plus P450 reductase thus appear to be excellent gene combinations for use with CPA in P450/prodrug activation-based cancer gene therapy.

¹ Supported in part by NIH Grant CA49248 (to D. J. W.). Y. J. received Postdoctoral Fellowship support from L'Association pour la Recherche sur le Cancer.

² To whom requests for reprints should be addressed, at Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215. Phone: (617) 353-7401; Fax: (617) 353-7404; E-mail: djw@bio.bu.edu.

Received 5/15/98. Accepted 8/ 3/98.

This article has been cited by other articles:

				J. Ma and D. J. Waxman Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890. [Abstract] [Full Text] [PDF]

				Y. Jounaidi, C.-S. Chen, G. J. Veal, and D. J. Waxman Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther., March 1, 2006; 5(3): 541 - 555. [Abstract] [Full Text] [PDF]

				C.-S. Chen, Y. Jounaidi, and D. J. Waxman ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OF R-IFOSFAMIDE AND S-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450 Drug Metab. Dispos., September 1, 2005; 33(9): 1261 - 1267. [Abstract] [Full Text] [PDF]

				J. P. Braybrooke, A. Slade, G. Deplanque, R. Harrop, S. Madhusudan, M. D. Forster, R. Gibson, A. Makris, D. C. Talbot, J. Steiner, et al. Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma Clin. Cancer Res., February 15, 2005; 11(4): 1512 - 1520. [Abstract] [Full Text] [PDF]

				E. Brantley, V. Trapani, M. C. Alley, C. D. Hose, T. D. Bradshaw, M. F. G. Stevens, E. A. Sausville, and S. F. Stinson FLUORINATED 2-(4-AMINO-3-METHYLPHENYL)BENZOTHIAZOLES INDUCE CYP1A1 EXPRESSION, BECOME METABOLIZED, AND BIND TO MACROMOLECULES IN SENSITIVE HUMAN CANCER CELLS Drug Metab. Dispos., December 1, 2004; 32(12): 1392 - 1401. [Abstract] [Full Text] [PDF]

				J. M. Shipley, C. H. Hurst, S. S. Tanaka, F. L. DeRoos, J. L. Butenhoff, A. M. Seacat, and D. J. Waxman trans-Activation of PPAR{alpha} and Induction of PPAR{alpha} Target Genes by Perfluorooctane-Based Chemicals Toxicol. Sci., July 1, 2004; 80(1): 151 - 160. [Abstract] [Full Text] [PDF]

				C.-S. Chen, J. T. Lin, K. A. Goss, Y.-a. He, J. R. Halpert, and D. J. Waxman Activation of the Anticancer Prodrugs Cyclophosphamide and Ifosfamide: Identification of Cytochrome P450 2B Enzymes and Site-Specific Mutants with Improved Enzyme Kinetics Mol. Pharmacol., May 1, 2004; 65(5): 1278 - 1285. [Abstract] [Full Text]

				Y. Jounaidi and D. J. Waxman Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy Cancer Res., January 1, 2004; 64(1): 292 - 303. [Abstract] [Full Text] [PDF]

				D. J. Waxman and P. S. Schwartz Harnessing Apoptosis for Improved Anticancer Gene Therapy Cancer Res., December 15, 2003; 63(24): 8563 - 8572. [Abstract] [Full Text] [PDF]

				C. H. Hurst and D. J. Waxman Activation of PPAR{alpha} and PPAR{gamma} by Environmental Phthalate Monoesters Toxicol. Sci., August 1, 2003; 74(2): 297 - 308. [Abstract] [Full Text] [PDF]

				P. S. Schwartz, C.-S. Chen, and D. J. Waxman Enhanced Bystander Cytotoxicity of P450 Gene-directed Enzyme Prodrug Therapy by Expression of the Antiapoptotic Factor p35 Cancer Res., December 1, 2002; 62(23): 6928 - 6937. [Abstract] [Full Text] [PDF]

				P. S. Schwartz and D. J. Waxman Cyclophosphamide Induces Caspase 9-Dependent Apoptosis in 9L Tumor Cells Mol. Pharmacol., December 1, 2001; 60(6): 1268 - 1279. [Abstract] [Full Text] [PDF]

				G. Xu and H. L. McLeod Strategies for Enzyme/Prodrug Cancer Therapy Clin. Cancer Res., November 1, 2001; 7(11): 3314 - 3324. [Abstract] [Full Text] [PDF]

				Y. Jounaidi and D. J. Waxman Frequent, Moderate-Dose Cyclophosphamide Administration Improves the Efficacy of Cytochrome P-450/Cytochrome P-450 Reductase-based Cancer Gene Therapy Cancer Res., June 1, 2001; 61(11): 4437 - 4444. [Abstract] [Full Text] [PDF]

				L. J. Yu, J. Matias, D. A. Scudiero, K. M. Hite, A. Monks, E. A. Sausville, and D. J. Waxman P450 Enzyme Expression Patterns in the NCI Human Tumor Cell Line Panel Drug Metab. Dispos., March 1, 2001; 29(3): 304 - 312. [Abstract] [Full Text]

				O. Dohr, M. J. I. Paine, T. Friedberg, G. C. K. Roberts, and C. R. Wolf Engineering of a functional human NADH-dependent cytochrome P450 system PNAS, January 2, 2001; 98(1): 81 - 86. [Abstract] [Full Text] [PDF]

				N. Ariyoshi, S. Imaoka, K. Nakayama, Y. Takahashi, K.-I. Fujita, Y. Funae, and T. Kamataki Comparison of the Levels of Enzymes Involved in Drug Metabolism between Transgenic or Gene-knockout and the Parental Mice Toxicol Pathol, January 1, 2001; 29(1_suppl): 161 - 172. [Abstract] [PDF]

				D. Zhou, Y. Lu, M. S. Steiner, and J. T. Dalton Cytochrome P-450 2C9 Sensitizes Human Prostate Tumor Cells to Cyclophosphamide via a Bystander Effect Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2659 - 2663. [Abstract] [Full Text]

				Y. Jounaidi and D. J. Waxman Combination of the Bioreductive Drug Tirapazamine with the Chemotherapeutic Prodrug Cyclophosphamide for P450/P450-Reductase-based Cancer Gene Therapy Cancer Res., July 1, 2000; 60(14): 3761 - 3769. [Abstract] [Full Text]